Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Vaxcyte Inc (PCVX) USD0.0013

Sell:$25.77 Buy:$25.88 Change: $0.40 (1.53%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.40 (1.53%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.40 (1.53%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Contact details

353 Hatch Dr
United States
+1 (650) 8370111

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.36 billion
Shares in issue:
52.19 million
United States
US dollar

Key personnel

  • Andrew Guggenhime
    President, Chief Financial Officer
  • Grant Pickering
    Chief Executive Officer, Co-Founder, Director
  • Jeff Fairman
    Co-Founder, Vice President - Research
  • Jim Wassil
    Chief Operating Officer
  • Paul Sauer
    Senior Vice President - Process Development & Manufacturing
  • Jane Wright-Mitchell
    Chief Compliance Officer , General Counsel , Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.